Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy

Advances in antibody engineering have led to the generation of more innovative antibody drugs, such as bispecific antibodies (bsAbs). Following the success associated with blinatumomab, bsAbs have attracted enormous interest in the field of cancer immunotherapy. By specifically targeting two differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tiancheng, Lin, Youpei, Gao, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038071/
https://www.ncbi.nlm.nih.gov/pubmed/36971124
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038071/
https://www.ncbi.nlm.nih.gov/pubmed/36971124
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0002

Ejemplares similares